Risk of declining sales due to competing and generic products

「Sales of the antineoplastic agent Opdivo intravenous infusion declined by ¥1.2 billion, or 4.1%, year on year to ¥28.2 billion due to intensifying competition and other factors.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, decreased by ¥6.0 billion, or 5.0%, from the previous fiscal year to ¥114.3 billion, due to the increasingly competitive environment and other factors.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥3.7 billion, or 10.9%, year on year to ¥37.8 billion, as use expanded in gastric cancer, esophageal cancer, urothelial cancer and other indications amid an increasingly competitive environment.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥29.9 billion, or 26.6%, from the previous fiscal year to ¥142.3 billion, as use expanded in gastric cancer, esophageal cancer and other indications, despite intensifying competition with competing products.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥24.1 billion, or 28.3%, year on year to ¥109.1 billion, as use expanded in gastric cancer, esophageal cancer and other indications, despite intensifying competition with competing products.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥13.8 billion, or 24.6%, year on year to ¥69.9 billion, as use expanded in gastric cancer, esophageal cancer and other indications, despite intensifying competition with competing products.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥5.1 billion, or 17.4%, year on year to ¥34.1 billion, as use expanded in first-line treatment of gastric cancer, adjuvant treatment after surgery for esophageal cancer and first-line treatment of non-small cell lung cancer, among other indications, despite intensifying competition with competing products.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥13.6 billion, or 13.8%, from the previous fiscal year to ¥112.4 billion, as use expanded in first-line treatment of non-small cell lung cancer, esophageal cancer and first-line treatment of gastric cancer, among other factors, despite intensifying competition with competing products.」

「• Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥8.7 billion, or 11.4%, year on year to ¥85.1 billion, as use expanded in first-line treatment of non-small cell lung cancer and second-line treatment of esophageal cancer, among other factors, despite intensifying competition with competing products. / • Sales of long-listed products were affected by measures promoting generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥3.7 billion, down 14.2% year on year, while sales of Rivastach patches, a treatment for Alzheimer’s disease, were ¥2.3 billion, down 61.0%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥2.4 billion, down 16.8% year on year, and Rivastach patches were ¥1.6 billion, down 61.7%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥1.2 billion, down 17.5% year on year, and Rivastach patches, a treatment for Alzheimer-type dementia, were ¥0.8 billion, down 60.7%.」

「Long-listed products were affected by measures to promote generic use. Sales of Rivastach patches, a treatment for Alzheimer-type dementia, were ¥6.6 billion, down 22.5% from the previous consolidated fiscal year; Opalmon tablets were ¥5.5 billion, down 34.5%; and Ricalbon tablets were ¥2.9 billion, down 39.9%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥2.9 billion, down 35.4% year on year; Ricalbon tablets were ¥1.5 billion, down 41.3%; and Emend capsules, a treatment for nausea and vomiting associated with oncology drug administration, were ¥1.5 billion, down 67.8%.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased by ¥2.1 billion, or 9.5%, year on year to ¥24.4 billion. This reflected expanded use in esophageal cancer, in addition to steady use in gastric cancer, renal cell carcinoma and other indications, despite intensifying competition with competing products.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased as its use expanded in renal cell carcinoma and other indications. However, due to the impact of the drug price review in November the year before last and intensifying competition with competing products, sales decreased by ¥3.3 billion, or 3.6%, from the previous fiscal year to ¥87.3 billion.」

「Sales of Opdivo intravenous infusion, an antineoplastic agent, increased as its use expanded in renal cell carcinoma and other indications. However, due to the impact of the drug price review in November the year before last and intensifying competition with competing products, sales decreased by ¥3.4 billion, or 4.7%, from the first nine-month period of the previous fiscal year to ¥68.0 billion. Sales of long-listed products were affected by measures promoting generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥6.7 billion, down 19.0% from the first nine-month period of the previous fiscal year, while sales of Ricalbon tablets, a treatment for osteoporosis, were ¥3.9 billion, down 36.7%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥4.5 billion, down 19.2% from the first six months of the previous fiscal year, and Ricalbon tablets were ¥2.6 billion, down 41.1%.」

「Although use of the oncology drug Opdivo intravenous infusion expanded for renal cell carcinoma, sales were ¥22.3 billion, down ¥0.5 billion, or 2.0%, from the first quarter of the previous consolidated fiscal year, due to the impact of the drug-price review in November last year and intensifying competition from competing products.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥10.4 billion, down 27.9% from the previous consolidated fiscal year, and Ricalbon tablets were ¥7.3 billion, down 32.8%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥8.3 billion, down 28.7% from the first nine months of the previous fiscal year, and Ricalbon tablets were ¥6.1 billion, down 28.3%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥5.5 billion, down 26.8% from the first six months of the previous fiscal year, and Ricalbon tablets, a treatment for osteoporosis, were ¥4.4 billion, down 19.0%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥2.9 billion, down 23.1% from the first quarter of the previous fiscal year; Onon capsules were ¥1.1 billion, down 14.6%; and Onon dry syrup was ¥0.7 billion, down 14.3%.」

「Sales of long-listed products were affected by measures promoting generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥14.4 billion, down 15.6% from the previous fiscal year; sales of Onon capsules, a treatment for bronchial asthma and allergic rhinitis, were ¥5.5 billion, down 19.5%; and sales of Onon dry syrup were ¥3.3 billion, down 18.8%.」

「Sales of long-listed products were affected by competing products and measures promoting generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥11.6 billion, down 13.0% from the first nine-month period of the previous fiscal year; sales of Onon capsules, a treatment for bronchial asthma and allergic rhinitis, were ¥3.9 billion, down 17.5%; and sales of Foipan tablets, a treatment for chronic pancreatitis and postoperative reflux esophagitis, were ¥2.4 billion, down 19.3%.」

「Sales of long-listed products were affected by competing products and measures promoting generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥7.5 billion, down 14.9% from the first six-month period of the previous fiscal year; sales of Onon capsules, a treatment for bronchial asthma and allergic rhinitis, were ¥2.4 billion, down 20.3%; and sales of Foipan tablets, a treatment for chronic pancreatitis and postoperative reflux esophagitis, were ¥1.6 billion, down 21.2%.」

「Sales of long-listed products were affected by competing products and measures promoting generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥3.8 billion, down 18.3% from the first quarter of the previous fiscal year; sales of Onon capsules, a treatment for bronchial asthma and allergic rhinitis, were ¥1.3 billion, down 22.9%; and sales of Foipan tablets, a treatment for chronic pancreatitis and postoperative reflux esophagitis, were ¥800 million, down 24.9%.」

「Long-listed products were affected by competing products and measures to promote generic use. Sales of Opalmon tablets were ¥17.0 billion, down 25.0% from the previous consolidated fiscal year; Onon capsules were ¥6.8 billion, down 24.2%; and Onon dry syrup was ¥4.1 billion, down 26.7%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥13.4 billion, down 26.3% from the first nine months of the previous fiscal year; Onon capsules were ¥4.8 billion, down 26.2%; and Foypan tablets were ¥3.0 billion, down 27.5%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥8.8 billion, down 25.9% from the first six months of the previous fiscal year; Onon capsules were ¥3.0 billion, down 25.6%; and Foypan tablets were ¥2.0 billion, down 27.0%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥4.7 billion, down 24.8% from the first quarter of the previous fiscal year; Onon capsules, a treatment for bronchial asthma and allergic rhinitis, were ¥1.7 billion, down 23.3%; and Foypan tablets, a treatment for chronic pancreatitis and postoperative reflux esophagitis, were ¥1.1 billion, down 25.6%.」

「Competition among domestic and overseas companies in the pharmaceutical industry is intensifying, and the Group's performance and financial position may be materially affected by sales of competing products and generics launched after pharmaceutical patents expire.」